Home/Pipeline/Amlitelimab

Amlitelimab

Moderate-to-Severe Atopic Dermatitis

Phase 3ActiveN/A

Key Facts

Indication

Moderate-to-Severe Atopic Dermatitis

Phase

Phase 3

Status

Active

Company

Sanofi

About Sanofi

Sanofi is a global biopharmaceutical leader with a mission to 'chase the miracles of science' by developing innovative medicines and vaccines. The company has strategically pivoted to become an R&D-driven, AI-powered organization, focusing its deep immunoscience expertise on high-growth areas like immunology and oncology. Its strategy is centered on accelerating drug discovery, optimizing its robust pipeline, and delivering compelling growth through breakthrough therapeutics.

View full company profile

Therapeutic Areas

Immunology Oncology Rare Diseases Neurology Vaccines

Other Moderate-to-Severe Atopic Dermatitis Drugs

Drug	Company	Phase	Status
Lebrikizumab	Eli Lilly	Regulatory Review	FDA Review
Zumilokibart (APG777)	Apogee Therapeutics	Phase 2	Active - Part B enrollment completed
APG279 (Zumilokibart + APG990)	Apogee Therapeutics	Phase 1	Active - fully enrolled
Ebglyss/Lebrikizumab	Almirall	Marketed/Registration	Launched in EU; Under Review in US
IDgenix (AdvanceAD Tx)	Castle Biosciences	Commercial/Early Launch	Active
Rademikibart (CBP-201)	Connect Biopharma	Phase 3	Active